Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

641
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
641
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

480
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
480
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

340
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
340
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

579
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
579
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

601
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
601

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Secukinumab for Giant Cell Arteritis.

NEJM evidence·2026
Same author

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

The New England journal of medicine·2026
Same author

Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists.

Rheumatology advances in practice·2026
Same author

A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Frailty and Associated Outcomes in Patients With Vasculitis.

The Journal of rheumatology·2025
Same author

Beyond Glucocorticoids for IgG4-Related Disease.

The New England journal of medicine·2025

Related Experiment Video

Updated: Apr 21, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K

Current therapies for ANCA-associated vasculitis.

Lindsay Lally1, Robert Spiera

  • 1Department of Medicine/Division of Rheumatology, Hospital for Special Surgery, New York, NY 10021; email: lallyl@hss.edu , spierar@hss.edu.

Annual Review of Medicine
|October 24, 2014
PubMed
Summary

ANCA-associated vasculitides like GPA, MPA, and EGPA are autoimmune diseases treated with glucocorticoids and other agents. Research focuses on optimizing maintenance therapy and developing targeted treatments to reduce damage and improve outcomes.

Keywords:
biologicseosinophilic granulomatosis with polyangiitis (Churg-Strauss)granulomatosis with polyangiitis (Wegener's)microscopic polyangiitis

More Related Videos

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

6.0K
Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
05:44

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

1.2K

Related Experiment Videos

Last Updated: Apr 21, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K
Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

6.0K
Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
05:44

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

1.2K

Area of Science:

  • Immunology
  • Rheumatology
  • Internal Medicine

Background:

  • ANCA-associated vasculitides (AAV) encompass granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).
  • These are multisystem autoimmune diseases defined by necrotizing small- to medium-vessel vasculitis and anti-neutrophil cytoplasmic antibodies (ANCA).

Purpose of the Study:

  • To review current therapeutic strategies for AAV, including induction and maintenance of remission.
  • To identify key treatment goals, such as reducing toxicity and preventing relapse.
  • To highlight future research directions in AAV management.

Main Methods:

  • Literature review of current therapeutic strategies for ANCA-associated vasculitides.
  • Analysis of treatment goals and emerging insights into disease pathogenesis.
  • Identification of future research priorities.

Main Results:

  • Current treatments involve glucocorticoids combined with conventional or biologic agents for remission induction and maintenance.
  • Primary treatment goals include minimizing therapy toxicity, preventing disease relapse, and reducing long-term damage and morbidity.
  • Emerging insights into AAV pathogenesis are guiding future research.

Conclusions:

  • Optimizing maintenance therapy duration and frequency is crucial.
  • Development of targeted therapeutic agents, informed by pathogenesis research, is a key future direction.
  • Reducing treatment-related morbidity and disease-related damage remains paramount in AAV management.